JP3993907B2 - Calcium absorption promoter - Google Patents
Calcium absorption promoter Download PDFInfo
- Publication number
- JP3993907B2 JP3993907B2 JP33753996A JP33753996A JP3993907B2 JP 3993907 B2 JP3993907 B2 JP 3993907B2 JP 33753996 A JP33753996 A JP 33753996A JP 33753996 A JP33753996 A JP 33753996A JP 3993907 B2 JP3993907 B2 JP 3993907B2
- Authority
- JP
- Japan
- Prior art keywords
- calcium
- curdlan
- calcium absorption
- heat
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は、加熱凝固性β−1,3−グルカン、好ましくはカードランを含有する腸管からのカルシウム吸収促進剤に関する。
【0002】
【従来の技術】
このところ、カルシウムの摂取不足が骨粗鬆症、高血圧、大腸癌などの重篤な疾病の原因となりうることが指摘され、カルシウム製剤とともにカルシウムの吸収を促進する成分の研究が盛んになってきている。
カルシウムの吸収を促進する成分としては、従来ビタミンDや乳糖、骨由来のペプチド(特開平4−16165号)、酪酸(特開平4−108360号)、ガラクトオリゴ糖(特開平4−134031号)、第一塩化鉄(特開平7−247218号)、タラまたはオキアミ由来の蛋白質(特開平7−194314号)、水溶性キトサン(特開平7−194316号)、豆乳蛋白質高分子画分(特開平7−75525号)などが提案されている。
【0003】
【発明が解決しようとする課題】
しかし従来技術において、ビタミンDは生体内でも合成される物質であるので、ビタミンDが充分に合成されている人はあまり効果が期待できないし、乳糖は乳糖不耐症の人には、下痢などの副作用が出る場合がある。また蛋白質やペプチド類は原料に由来する臭味のあることが多くその他の糖類も製造コスト的に問題があり実用化は困難である。
本発明者らは、容易に且つ廉価に入手しうるもので腸管からのカルシウムの吸収を促進させる成分はないかと種々研究を重ねていたが、意外にも従来食品類の製造に凝固剤や結合剤として用いられてきた加熱凝固性β−1,3−グルカン類がカルシウムの腸管吸収を促進させることをつきとめ、さらに研究を進めて本発明を完成した。
【0004】
【課題を解決するための手段】
すなわち、本発明は
(1)加熱凝固性β−1,3−グルカンを含有してなるカルシウム吸収促進剤、および
(2)加熱凝固性β−1,3−グルカンがカードランである前記(1)記載のカルシウム吸収促進剤、
である。
【0005】
【発明の実施の形態】
本発明に用いられる加熱凝固性β−1,3−グルカンは、グルコースが主にβ−1,3−結合によって結合されている加熱凝固性を有する多糖類である。その起源は特に限定されず、微生物、動物、植物、その他いずれの起源であってもよいが、好ましいものは微生物由来のものである。微生物由来の多糖類としては、例えばカードラン、パラミロン、パキマン等が挙げられ、このうち特に好ましいものはカードランである。
カードランは微生物により生産されるグルコースが主にβ−1,3−結合によって結合されている加熱凝固性を有する多糖類であり、たとえば、アルカリゲネス属またはアクロバクテリウム属の微生物によって生産される多糖類が挙げられる。具体的には、アルカリゲネス・フェカリス・バール・ミクソゲネス菌株10C3Kにより生産される多糖類〔アグリカルチュラル・バイオロジカル・ケミストリー(Agricultural Biological Chemistry)、30巻、196頁(1966)〕、アルカリゲネス・フェカリス・バール・ミクソゲネス菌株10C3Kの変異株NTK−u(IFO 13140)により生産される多糖類(特公昭48−32673号)、アクロバクテリウム・ラジオバクター(IFO 13127)およびその変異株U−19(IFO 13126)により生産される多糖類(特公昭48−32674号)などが使用できる。
パラミロンは、微生物により生産される多糖類であり、例えばユーグレナ属の微生物によって生産されるものが挙げられる。具体的にはユーグレナ・グラシリス・クレブス(Euglena gracilis Klebs)NIES−47、ユーグレナ・グラシリス・クレブス NIES−48、ユーグレナ・グラシリス・バラエティ・バチラリス・プリンシェイム(Euglena gracilis var. bacillaris pringsheim)NIES−49等により生産される多糖類が挙げられる。これらの菌は、(財)地球・人間環境フォーラムに保管されている公知菌株である。本発明では該多糖類に加熱凝固性をもたせたものが使用され得る。たとえば前記多糖類をアルカリで溶解後、不溶物を除去し、pH10以下に調整して析出したものが用いられる。
パキマンはポリア・コカス(Poria cocas)菌核グルカンである。
【0006】
これらの加熱凝固性β−1,3−グルカンは単独で投与してもよく、また自体公知のカルシウム剤と共に経口投与するとより効果的であり、カルシウム摂取の欠乏による種々の疾病たとえば骨粗鬆症、くる病等の予防、治療に有効である。カルシウム剤としてはたとえば、炭酸カルシウム、リン酸カルシウム、水酸化カルシウム、乳酸カルシウム、グルコン酸カルシウム、カキ殻、サンゴ等由来の貝カルシウム、コンブ、ヒジキ、ワカメなどの藻類由来のカルシウム、脊椎動物の骨や卵殻由来のカルシウムなどが挙げられる。
本発明に用いられる加熱凝固性β−1,3−グルカンは、既に述べたとおり食品の材料として用いられてきたものであるので、それを含む食品として日常の食生活において適量を摂取することができる。
摂取量に関しては、特に制限はないが、大人1日当たり0.1〜10g、好ましくは、0.5〜5g程度を経口投与する。また、飼料中に添加して家禽、家畜などの動物に与え、栄養の改善を図ることもできる。またカルシウム剤と共に他の賦形剤、増量剤などと共に錠剤、顆粒剤、カプセル剤、シロップ剤等の形態で医薬品とすることもできる。
【0007】
【実施例】
以下に実施例、実験例をあげて本発明をさらに詳細に説明するが、本発明はそれらにより限定されるものではない。
実施例1
小麦粉450g、砂糖220g、全卵70g、バター180g、カードラン50g、炭酸カルシウム20g、ベイキングパウダー6g、食塩2g、バニラエッセンス2gを用いて生地を生成し、冷却した後、整形して焙焼しクッキーを調製した。
実施例2
温水150gに砂糖26g、粉末ゼラチン5gを添加し溶解させた後、レモン果汁6g、レモンの皮3g、カードラン6g、炭酸カルシウム3g、ホワイトキュラソー1gを加え撹拌しゼリー型に入れた。冷蔵庫で4時間冷却しレモンゼリーを得た。
【0008】
実施例3
〔錠剤〕
炭酸カルシウム 40g
カードラン 40g
乳糖 30g
澱粉 82g
カルボキシメチルセルロース 3g
ステアリン酸マグネシウム 5g
粉末状の上記成分を用いて常法により顆粒化し、打錠(1錠200mg、直系6.0mm)して、1錠当たりカルシウム16mg、カードランを40mg含有する普通面の錠剤を1000錠製造した。
実施例4〜6
〔表1〕に示す組成を有する飼料を調製し、それぞれ対照食、実施例4〜6とした。
実験例1
9週齢のSD計雄性ラット6匹を1群とし、セルロースを10重量%含む対照食を対照群、このセルロースの10重量%を全て前記カードランに置き換えたものを実施例4群とした。
【0009】
【表1】
水と対照食あるいは実施例4の飼料を5日間自由に摂取させ、給餌開始後3日目より2日間出納実験を行った。飼料摂取量は給餌した飼料の重量から残された飼料の重量を差し引くことにより求めた。出納実験終了後、糞を採取し、110℃の恒温器内で3時間乾燥させた。この糞を粉砕機で砕き、さらに乳鉢で細かくすり潰した後、3Nの塩酸に溶解し、カルシウムの含有量をカルシウム測定キット、カルシウムE−テストワコー(和光純薬工業株式会社製)を用いて測定し、糞中のカルシウム含有率を求めた。各実験飼料中のカルシウム含有率は0.536%であり、下式によりカルシウム(Ca)の見かけの吸収率を算出した。
【0010】
【数1】
摂食量(カルシウム摂取量)、糞中カルシウム排泄量およびカルシウム吸収率をノンパラメトリック検定により有意差検定した。その結果を〔表2〕に示す。実施例4群は対照群より著しく高い吸収率が認められ、危険率1%で有意差が示された。
【0011】
【表2】
【0012】
実験例2
9週齢のSD系雄性ラット8匹を1群とした。飼料組成は、〔表1〕に記載の実験例1で使用したセルロースを10重量%含む対照食を対照群とし、このセルロース7.5重量%を前記カードランに置き換えたものを実施例5群とした。
実験例1と同様に、水と対照食あるいは実施例5の飼料を5日間自由に摂取させ、給餌開始後3日目より2日間出納実験を行った。実験終了後、摂食量(カルシウム摂取量)、糞中カルシウム排泄量およびカルシウム吸収率を実験例1に記載の計算式より算出し、ノンパラメトリック検定により有意差検定した。その結果を〔表3〕に示す。実施例5群は対照群よりも高い吸収率が認められ、危険率5%で有意差が示された。
【0013】
【表3】
【0014】
実施例3
11週齢のSD系雄性ラット6匹を1群とした。飼料組成は、〔表1〕に記載のセルロースを10重量%含む対照食を対照群とし、このセルロース2.5重量%を前記カードランに置き換えたものを実施例6群とした。実験例1と同様に、水と対照食あるいは実施例6の飼料を5日間自由に摂取させ、給餌開始後3日目より2日間出納実験を行った。実験終了後、摂取量(カルシウム摂取量)、糞中カルシウム排泄量およびカルシウム吸収率を実験例1に記載の計算式より算出し、ノンパラメトリック検定により有意差検定した。その結果を〔表4〕に示す。実施例6群は対照群よりも高い吸収率が認められ、危険率5%で有意差が示された。またこの試験に用いたカードランの配合量はカルシウムの吸収を促進すると言われている乳糖の必要量よりも低いものであった。これらの結果から、カードランは低濃度でも腸管からのカルシウム吸収を促進する作用を有することが示された。
【0015】
【表4】
【0016】
【発明の効果】
経口的にカルシウム摂取はしているものの、腸管からのカルシウム吸収が充分でないため体内でのカルシウムが不足勝ちな人や哺乳動物が存在する。それらの人その他の哺乳動物に加熱凝固性β−1,3−グルカンを含有してなる医薬、食品、飼料を与えることにより、経口的に摂取したカルシウムを効率よく腸管から体内に吸収させることができる。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a calcium absorption promoter from the intestinal tract containing heat-coagulating β-1,3-glucan, preferably curdlan.
[0002]
[Prior art]
Recently, it has been pointed out that insufficient intake of calcium can cause serious diseases such as osteoporosis, hypertension, and colorectal cancer, and research on ingredients that promote calcium absorption along with calcium preparations has become active.
Examples of ingredients that promote calcium absorption include vitamin D, lactose, bone-derived peptides (JP-A-4-16165), butyric acid (JP-A-4-108360), galactooligosaccharides (JP-A-4-14031), Ferrous chloride (JP-A-7-247218), protein derived from cod or krill (JP-A-7-194314), water-soluble chitosan (JP-A-7-194316), soy milk protein polymer fraction (JP-A-7 -75525) and the like have been proposed.
[0003]
[Problems to be solved by the invention]
However, in the prior art, vitamin D is a substance that is also synthesized in the living body. Therefore, a person who has sufficiently synthesized vitamin D cannot expect much effect, and lactose is not suitable for those who are lactose intolerant. Side effects may occur. Proteins and peptides often have odors derived from the raw materials, and other saccharides also have problems in production cost and are difficult to put into practical use.
The inventors of the present invention have repeatedly studied whether there are ingredients that can be easily and inexpensively obtained and promote absorption of calcium from the intestinal tract. The inventors have found that heat-coagulating β-1,3-glucans that have been used as agents promote the intestinal absorption of calcium, and further researched to complete the present invention.
[0004]
[Means for Solving the Problems]
That is, the present invention relates to (1) a calcium absorption promoter comprising heat-coagulating β-1,3-glucan, and (2) the heat-coagulating β-1,3-glucan is curdlan (1 ) Calcium absorption enhancer as described,
It is.
[0005]
DETAILED DESCRIPTION OF THE INVENTION
The heat-coagulating β-1,3-glucan used in the present invention is a polysaccharide having heat-coagulating properties in which glucose is mainly bound by β-1,3-bonds. The origin is not particularly limited, and any origin may be a microorganism, an animal, a plant, or the like, but a preferred one is derived from a microorganism. Examples of the microorganism-derived polysaccharide include curdlan, paramylon, and pachyman, and among these, curdlan is particularly preferable.
Curdlan is a heat-coagulable polysaccharide in which glucose produced by microorganisms is bound mainly by β-1,3-linkages. For example, curdlan is produced by microorganisms belonging to the genus Alkagenes or Acrobacterium. Examples include sugars. Specifically, the polysaccharide produced by Alkaligenes faecalis var Myxogenes strain 10C3K [Agricultural Biological Chemistry, 30, 196 (1966)], Alkaligenes faecalis bur. By a polysaccharide (Japanese Patent Publication No. 48-32673) produced by a mutant NTK-u (IFO 13140) of Myxogenes strain 10C3K, Acrobacterium radiobacter (IFO 13127) and its mutant U-19 (IFO 13126) The produced polysaccharide (Japanese Examined Patent Publication No. 48-32684) can be used.
Paramylon is a polysaccharide produced by microorganisms, and examples thereof include those produced by Euglena microorganisms. Specifically, by Euglena gracilis Klebs NIES-47, Euglena gracilis Krebs NIES-48, Euglena gracilis var. Bacillaris pringsheim NIES-49, etc. Examples include polysaccharides that are produced. These bacteria are well-known strains stored in the Earth / Human Environment Forum. In the present invention, the polysaccharide having heat coagulation property can be used. For example, after the polysaccharide is dissolved with an alkali, insolubles are removed, and the pH is adjusted to 10 or lower and precipitated.
Pakiman is a Poria cocas sclerotia glucan.
[0006]
These heat-coagulating β-1,3-glucans may be administered alone or are more effective when administered orally together with a calcium agent known per se, and various diseases such as osteoporosis and rickets due to lack of calcium intake. It is effective for prevention and treatment. Examples of calcium agents include calcium carbonate, calcium phosphate, calcium hydroxide, calcium lactate, calcium gluconate, oyster shells, coral shells, calcium derived from algae such as kombu, hijiki and seaweed, vertebrate bones and eggshells. And calcium derived from it.
Since the heat-coagulable β-1,3-glucan used in the present invention has been used as a food material as described above, an appropriate amount can be ingested in daily eating habits as a food containing it. it can.
Although there is no restriction | limiting in particular regarding ingestion amount, 0.1-10g per day for an adult, Preferably, about 0.5-5g is orally administered. Moreover, it can be added to feed and given to animals such as poultry and livestock to improve nutrition. Moreover, it can also be set as a pharmaceutical in the form of a tablet, a granule, a capsule, a syrup, etc. with other excipient | fillers, a filler, etc. with a calcium agent.
[0007]
【Example】
Hereinafter, the present invention will be described in more detail with reference to examples and experimental examples, but the present invention is not limited thereto.
Example 1
450 g of wheat flour, 220 g of sugar, 70 g of whole eggs, 180 g of butter, 50 g of curdlan, 20 g of calcium carbonate, 6 g of baking powder, 2 g of salt, 2 g of vanilla essence, cooled, shaped, roasted and baked Was prepared.
Example 2
After adding 26 g of sugar and 5 g of powdered gelatin to 150 g of warm water, 6 g of lemon juice, 3 g of lemon peel, 6 g of curdlan, 3 g of calcium carbonate, and 1 g of white curacao were added and stirred to form a jelly type. It was cooled in the refrigerator for 4 hours to obtain lemon jelly.
[0008]
Example 3
〔tablet〕
40g calcium carbonate
40g card run
Lactose 30g
82g starch
Carboxymethylcellulose 3g
Magnesium stearate 5g
The above ingredients in powder form were granulated by a conventional method, and tableted (1 tablet 200 mg, direct 6.0 mm) to produce 1000 ordinary tablets containing 16 mg calcium and 40 mg curdlan per tablet. .
Examples 4-6
A feed having the composition shown in [Table 1] was prepared and used as a control food and Examples 4 to 6, respectively.
Experimental example 1
A group of 6 9-week-old male SD rats, one group, a control diet containing 10% by weight of cellulose, and a group of Example 4 in which all 10% by weight of the cellulose was replaced with the curdlan.
[0009]
[Table 1]
Water and a control diet or the feed of Example 4 were freely consumed for 5 days, and a balance experiment was conducted for 2 days from the 3rd day after the start of feeding. The feed intake was determined by subtracting the remaining feed weight from the fed feed weight. After completion of the cashier experiment, feces were collected and dried in a thermostat at 110 ° C. for 3 hours. The feces are crushed with a pulverizer, ground finely in a mortar, dissolved in 3N hydrochloric acid, and the calcium content is measured using a calcium measurement kit, Calcium E-Test Wako (manufactured by Wako Pure Chemical Industries, Ltd.). Then, the calcium content in feces was determined. The calcium content in each experimental feed was 0.536%, and the apparent absorption rate of calcium (Ca) was calculated by the following equation.
[0010]
[Expression 1]
Food intake (calcium intake), fecal calcium excretion, and calcium absorption rate were tested for significant differences by nonparametric test. The results are shown in [Table 2]. The Example 4 group showed a significantly higher absorption rate than the control group, and showed a significant difference at a risk rate of 1%.
[0011]
[Table 2]
[0012]
Experimental example 2
A group of 8 9-week-old male SD rats. For the feed composition, a control diet containing 10% by weight of cellulose used in Experimental Example 1 described in [Table 1] was used as a control group, and 7.5% by weight of this cellulose was replaced with the curdlan in Example 5 group. It was.
In the same manner as in Experimental Example 1, water and a control diet or the feed of Example 5 were freely ingested for 5 days, and a balance experiment was conducted for 2 days from the 3rd day after the start of feeding. After the experiment was completed, food intake (calcium intake), fecal calcium excretion, and calcium absorption rate were calculated from the formulas described in Experimental Example 1, and a significant difference test was performed by a nonparametric test. The results are shown in [Table 3]. The Example 5 group showed a higher absorption rate than the control group, and showed a significant difference at a risk rate of 5%.
[0013]
[Table 3]
[0014]
Example 3
Six 11-week-old SD male rats were used as one group. For the feed composition, a control diet containing 10% by weight of the cellulose described in [Table 1] was used as a control group, and 2.5% by weight of this cellulose was replaced with the curdlan as Example 6 group. In the same manner as in Experimental Example 1, water and a control diet or the feed of Example 6 were freely ingested for 5 days, and a balance experiment was conducted for 2 days from the 3rd day after the start of feeding. After the experiment was completed, the intake (calcium intake), fecal calcium excretion and calcium absorption rate were calculated from the formulas described in Experimental Example 1, and a significant difference test was performed by a nonparametric test. The results are shown in [Table 4]. The Example 6 group showed a higher absorption rate than the control group, and showed a significant difference at a risk rate of 5%. The amount of curdlan used in this test was lower than the required amount of lactose, which is said to promote calcium absorption. From these results, it was shown that curdlan has an action of promoting calcium absorption from the intestinal tract even at a low concentration.
[0015]
[Table 4]
[0016]
【The invention's effect】
Although there are calcium intakes orally, there are people and mammals who are short of calcium in the body because of insufficient calcium absorption from the intestinal tract. By giving medicines, foods, and feeds containing heat-coagulating β-1,3-glucan to those humans and other mammals, it is possible to efficiently absorb orally ingested calcium from the intestinal tract into the body. it can.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP33753996A JP3993907B2 (en) | 1996-12-02 | 1996-12-02 | Calcium absorption promoter |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP33753996A JP3993907B2 (en) | 1996-12-02 | 1996-12-02 | Calcium absorption promoter |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10158173A JPH10158173A (en) | 1998-06-16 |
JP3993907B2 true JP3993907B2 (en) | 2007-10-17 |
Family
ID=18309613
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP33753996A Expired - Lifetime JP3993907B2 (en) | 1996-12-02 | 1996-12-02 | Calcium absorption promoter |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3993907B2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004292382A (en) * | 2003-03-27 | 2004-10-21 | Kirin Brewery Co Ltd | Agent for promoting absorption of mineral, and agent for preventing and/or ameliorating osteoporosis |
JP5866693B2 (en) * | 2011-09-30 | 2016-02-17 | 株式会社ユーグレナ | Precancerous lesion occurrence inhibitor and method for colorectal cancer |
CN102557797B (en) * | 2011-12-31 | 2013-09-25 | 河海大学 | Preparation method of compound microbial calcium agent |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4689228A (en) * | 1985-08-26 | 1987-08-25 | University Patents, Inc. | Enhanced absorption of dietary mineral components |
JP2947484B2 (en) * | 1990-05-08 | 1999-09-13 | 雪印乳業株式会社 | Bone-fortified food, feed or osteoarthritis prophylactic or therapeutic drug |
JPH05295003A (en) * | 1990-07-04 | 1993-11-09 | Takeda Chem Ind Ltd | Production of beta-1,3-glucan |
JP2890379B2 (en) * | 1990-08-28 | 1999-05-10 | 雪印乳業株式会社 | Calcium absorption promoting nutrient, food and feed |
JP3179090B2 (en) * | 1990-09-25 | 2001-06-25 | 日新製糖株式会社 | Calcium absorption promoter |
JP3143622B2 (en) * | 1992-03-31 | 2001-03-07 | 雪印乳業株式会社 | Edible cold insulation / warming agent and method for producing the same |
JP3260491B2 (en) * | 1993-06-30 | 2002-02-25 | 株式会社紀文フードケミファ | Calcium absorption promoting composition containing soymilk protein polymer fraction or soymilk peptide |
JP3397258B2 (en) * | 1993-12-29 | 2003-04-14 | 日本水産株式会社 | Calcium absorption promoting water-soluble fraction, composition containing the same, and calcium absorption promoting additive |
JP3393560B2 (en) * | 1993-12-29 | 2003-04-07 | 日本水産株式会社 | Calcium absorption promoting composition containing water-soluble chitosan and additive for promoting calcium absorption |
JPH07247218A (en) * | 1994-03-10 | 1995-09-26 | Sapooto:Kk | Calcium pharmaceutical preparation improved in absorbability and method for improving absorption of calcium |
JPH07250652A (en) * | 1994-03-11 | 1995-10-03 | Tsubuki Kk | Preparation of chopped food |
JP3240102B2 (en) * | 1994-08-11 | 2001-12-17 | 江崎グリコ株式会社 | Phosphorylated sugar and method for producing the same |
JP2770134B2 (en) * | 1994-08-22 | 1998-06-25 | 信久 川野 | Manufacturing method of fish meat paste product and fish meat paste product-like food |
-
1996
- 1996-12-02 JP JP33753996A patent/JP3993907B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JPH10158173A (en) | 1998-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4249853B2 (en) | Oral skin moisturizer | |
JP3020387B2 (en) | Antiviral substance | |
JP4667568B2 (en) | Immune enhancing composition | |
JPH0745521B2 (en) | Antihypertensive agent having antihypertensive effect | |
JPH09191852A (en) | Healthy food | |
JP3160862B2 (en) | Bone-fortified foods, feeds and pharmaceuticals | |
JP2639726B2 (en) | Water-soluble dietary fiber and method for producing the same | |
JPWO2007086100A1 (en) | Composition having blood pressure lowering action and / or elevation suppressing action and food and drink containing the same | |
JPH05255097A (en) | Liquid composition | |
JP3393560B2 (en) | Calcium absorption promoting composition containing water-soluble chitosan and additive for promoting calcium absorption | |
JP5349744B2 (en) | Mineral absorption promoter, food and feed | |
JP3993907B2 (en) | Calcium absorption promoter | |
JP2002209553A (en) | Carcinostatic healthy food and additive for healthy food | |
JP2003146887A (en) | Formulation and food and drink having nk cell- activating effect | |
EP3530281A1 (en) | New process of preparation of glycan compositions & uses thereof | |
JPH05238945A (en) | Intestinal environment-improving agent | |
JP2002275087A (en) | Antidiabetic medicine and food for preventing diabetes | |
JPWO2007144943A1 (en) | Immune function enhancing composition | |
JP4001443B2 (en) | Phosphorus absorption inhibitor and therapeutic agent containing the same | |
JP4493736B2 (en) | Mineral absorption promoting composition containing chitin and additive for promoting mineral absorption | |
JP4721684B2 (en) | Oral composition containing difructose anhydride | |
JP2632577B2 (en) | Hyperuricemia improving agent and food for improvement | |
JPH08322506A (en) | Health-assisting food | |
JP2003277273A (en) | Mineral absorption-promoting agent | |
US20080103089A1 (en) | Compounds, Compositions, Formulations and Process for Preparation Thereof and Method of Treatment and Management of Acidity and Related Disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20031117 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070717 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070730 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100803 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110803 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120803 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130803 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |